The FDA has approved Eli Lilly’s Mounjaro (tirzepatide) for a new indication: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. The approval, dated August 28, 2026, marks the first cardiovascular indication for tirzepatide.
The decision expands Mounjaro’s approved uses beyond blood glucose management, addressing a serious and common complication of type 2 diabetes. It also gives clinicians a formally approved option that targets both glycemic control and cardiovascular risk within a single therapy.
What happened
The FDA approved Mounjaro to lower the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes at high cardiovascular risk. The approval was based on the SURPASS-CVOT trial, described as the first cardiovascular outcomes trial to compare two incretin medicines head-to-head.
The trial enrolled more than 13,000 participants across 30 countries and ran for more than four and a half years. Mounjaro demonstrated an 8% lower rate of cardiovascular death, heart attack, or stroke compared to Trulicity (dulaglutide), with an estimated hazard ratio of 0.92 (95.3% CI: 0.83–1.01). The result met the trial’s non-inferiority endpoint, meaning tirzepatide was shown not to be worse than dulaglutide for cardiovascular outcomes. The confidence interval’s upper bound of 1.01 indicates the trial did not establish statistical superiority over dulaglutide for this endpoint.
Why it matters
This is the first FDA approval of tirzepatide for cardiovascular risk reduction, expanding Mounjaro’s label beyond glucose management. Cardiovascular events are a serious and common complication of type 2 diabetes, and the approval gives clinicians a formally recognized option for addressing both glycemic control and cardiovascular risk in a single therapy.
The decision is likely to influence payer coverage decisions, prescribing patterns, and the competitive landscape among GLP-1 receptor agonists and dual GIP/GLP-1 agonists. Because the trial met a non-inferiority endpoint rather than demonstrating superiority, the approval reflects comparable cardiovascular outcomes versus dulaglutide rather than a proven greater cardiovascular benefit.
What to watch next
- How payers and insurers respond to the expanded indication, including any updates to formulary placement and coverage criteria.
- Whether prescribing patterns shift among endocrinologists, cardiologists, and primary care providers treating adults with type 2 diabetes at high cardiovascular risk.
- How competing GLP-1 and dual GIP/GLP-1 agonist manufacturers position their products in response to Mounjaro’s broader label.
- Whether further analyses from SURPASS-CVOT or subsequent trials explore superiority endpoints for tirzepatide in cardiovascular outcomes.
Sources
BioSpace / Eli Lilly PR Newswire
Industry information only. Not medical or legal advice.
